FRA-1, a member of the FOS family of transcription factors, is overexpressed in a variety of human tumors, and contributes to tumor progression. In addition to mitogens, various toxicants and carcinogens persistently induce FRA-1 expression in vitro and in vivo. Although the mitogen induced expression of c-FOS is relatively well understood, it is poorly defined in the case of FRA-1. Our recent analysis of the FRA-1 promoter has shown a critical role for a TRE located at À318 in mediating the TPA-induced expression. The À379 to À283 bp promoter segment containing a critical TRE (À318), however, is insufficient for the induction of FRA-1 promoter. Here, we show that a 40-bp (À276/À237) segment, comprising a TCF binding site and the CArG box (collectively known as serum response element, SRE), and an ATF site, is also necessary for the FRA-1 induction by TPA and EGF. Interestingly, the À283 to þ 32 bp FRA-1 promoter fragment containing an SRE and an ATF site alone was also insufficient to confer TPA sensitivity to a reporter gene. However, in association with the À318 TRE, the SRE and ATF sites imparted a strong TPA-inducibility to the reporter. Similarly, EGF also required these motifs for the full induction of this gene. Using ChIP assays we show that, in contrast to c-Jun, SRF, Elk1, ATF1 and CREB proteins bind to SRE and ATF sites of the FRA-1 promoter, constitutively. RNAi-mediated knockdown of endogenous SRF, ELK1 and c-JUN protein expression significantly reduced TPA-stimulated FRA-1 promoter activity. Thus, a bipartite enhancer formed by an upstream TRE and the downstream SRE and ATF sites and the cognate factors is necessary and sufficient for the regulation of FRA-1 in response to mitogens.
Introduction
The activator protein 1 (AP1) family of transcription factors acts as a 'master switch' for diverse extracellular stimuli (Eferl and Wagner, 2003) . Two distinct AP1 proteins belonging to the FOS (c-FOS, FOS-B, DFOS-B, FRA-1 and FRA-2) and JUN (c-JUN, JUN-B and JUN-D) subclasses are important for regulating transcription. In general, the FOS proteins form heterodimers with the JUN protein families thereby regulating gene expression from 12-O-tetradecanoylphorbol-13-acetate (TPA) response element (TRE) and TRE-like elements present in various promoters (Chinenov and Kerppola, 2001 ). However, the AP1 dimers formed by various members of this family can drive exclusive as well as overlapping sets of genes depending on their spatiotemporal expression, relative abundance, cell type and ligand-specified post-transcriptional modifications (Tulchinsky, 2000) .
Emerging evidence suggests an important role for FRA-1 in cell motility, invasion, and maintenance and progression of the transformed state in several cell types (Tulchinsky, 2000) . For instance, overexpression of fra-1, but not its closest relative fra-2, activates the transcription of genes associated with tumor progression (Kustikova et al., 1998; Andersen et al., 2002) . Fra-1 also enhances cell motility and growth of epitheloid cancer cells in soft agar (Vallone et al., 1997; Kustikova et al., 1998) . Overexpressed fra-1 in fibroblasts causes anchorage-independent cell growth and oncogenic transformation (Wisdom and Verma, 1993; Bergers et al., 1995) . Consistent with these observations, a high level of fra-1 expression is found in various tumors and tumorogenic cell lines (Matsui et al., 1990; Hu et al., 2001; Zajchowski et al., 2001; . Indeed, fra-1 transgenic mice develop lung tumors (Jochum et al., 2000) . Several lines of recent evidence have also indicated a potential role for FRA-1 in abnormal differentiation and transformation of lung cells. For example, various toxicants and known carcinogens, such as tobacco smoke, silica and asbestos, persistently activate fra-1 but not fra-2 expression in lung cells (Reddy and Mossman, 2002) . We have shown that FRA-1 upregulates the expression of genes associated with airway squamous cell metaplasia (Patterson et al., 2001) and that of matrix metalloproteinase-9, which is implicated in toxin-induced respiratory pathogenesis (Parks and Shapiro, 2001) . Since an upregulation of FRA-1, rather than a mutational activation, contributes to the growth and proliferation of human tumors, it is important to understand its regulation. In particular, the cis-elements and cognate trans-factors as well as the signal transduction pathways controlling the induction of FRA-1 in response to various mitogens, cytokines, toxicants and carcinogens has not been understood.
The temporal control of the FRA-1 and c-FOS genes is distinct. The promoter of c-FOS contains several ciselements. Notably, a serum response element (SRE), which encompasses a ternary complex factor (TCF) binding site, an SRF binding element or CArG box, and an activating transcription factor (ATF/CREB) binding site, plays a major role in the induction of c-fos (Treisman, 1995; Whitmarsh et al., 1995) in response to mitogenic stimuli. Both TCF and ATF sites are required for a high-level induction of c-fos by TPA (Robertson et al., 1995; Soh et al., 1999; Wang and Prywes, 2000) . TPA-activation of Elk1, ATF1 and CREB proteins has been mainly attributed to such induction (Wang and Prywes, 2000) . A delayed induction of FRA-1 has been mainly attributed to a lack of c-fos SRE-like sequences (Bergers et al., 1995; Schreiber et al., 1997) .
We have recently demonstrated that the -379 to þ 32 bp genomic sequence, devoid of introns, contains sufficient information to drive FRA-1 transcription in response to diverse stimuli in several lung cell types (Adiseshaiah et al., 2003) . The TPA inducible transcription of FRA-1 is mainly dependent on a TRE located at À318. Chromatin immunoprecipitation (ChIP) assays have revealed an enhanced recruitment of c-JUN, and FRA-2 to the FRA-1 promoter following TPA treatment. Here, we report that an SRE-like DNA segment is necessary to confer TPA inducibility of FRA-1 transcription. Further, we demonstrate a role for SRF, TCFs, such as Elk1, and ATF1 and CREB proteins in the regulation of FRA-1 transcription.
Results
The À274 to À237 segment of the FRA-1 containing a c-FOS SRE-like sequence is required for TPA and EGF-inducible transcription
We found that the À379 to þ 32 bp 5 0 -flanking region ( Figure 1a ) mediated a high level of TPA-inducible FRA-1 promoter activity in human pulmonary (A549 and 1HAEo) and breast (MCF-7) epithelial cell lines, respectively, as compared to the À283 to þ 32 bp segment. Recently, we have shown that the À318 TRE of the FRA-1 promoter is necessary for its TPAinducible expression in A549 cells (Adiseshaiah et al., 2003) . We have shown that c-JUN and FRA-2 proteins are recruited to the endogenous FRA-1 promoter following TPA stimulation. In the present study, we examined whether the promoter region encompassing À318 TRE alone could confer the mitogenic response to a heterologous promoter. The À379/À269 bp fragment of the FRA-1 promoter was cloned upstream of the SV-40 early promoter in the pGL3-promoter vector, to generate À379/À269 SV-Luc (Figure 1b ). Cells were transfected with À379/À269 SV-Luc, serum-starved and then stimulated with DMSO, TPA or EGF. The basal activity of the À379/À269 SV-Luc was similar to that of parent vector SV-Luc. Interestingly, TPA, EGF and serum (data not shown) failed to stimulate the À379/ À269 SV-Luc beyond its basal level, suggesting a requirement for additional cis-element(s) to confer mitogen-induced response.
We next examined whether inclusion of a DNA segment located between À276 and À239 could restore mitogen inducibility to the promoter. We chose this region because it exhibited a high homology (see below) to the SRE of c-FOS. Indeed, inclusion of this DNA segment restored TPA, EGF and serum (data not shown) response to the À379/À269-SV-Luc (Figure 1b) . These results indicate that the À379/À237 region is sufficient for high-level TPA and EGFinducible FRA-1 transcription. To demonstrate the importance of the À379/À269 enhancer fragment, we generated the À379/À237 SV-Luc construct bearing mutations in the À318 TRE and analysed the promoter activity in response to TPA, EGF and serum. Mutation of this site drastically reduced TPA, EGF and serum (data not shown) inducibility. Thus, the À318 TRE is critical for mitogen-sensitivity even in the context of a neutral promoter.
The À379 to À237 enhancer elements are conserved across species Alignment of the human, mouse and rat promoters revealed that several crucial elements are conserved across species (Figure 2a ). In particular, we found that the À276 to À239 bp segment of FRA-1 contained a putative ATF site, and a TCF site and the CArG box (hereafter referred to as the, SRE). Sequence analysis also indicated that the positions and orders of the À318 TRE, À343 GC box, and À377 EBS (Etsbinding site) were highly conserved (Figure 2a ). We next compared the SREs of the members of the FOS family. Putative SREs were well conserved among all members of the FOS family. The SREs and ATF sites of all FOS family members are separated by five nucleotides (Figure 2b) . However, the distances between the TCF site and the CArG box are different for FRA-1 (6 bp) and c-FOS (2 bp). Whether this difference accounts for the distinct kinetics of expression of c-FOS and FRA-1 is unclear.
Mutations in the SRE and ATF sites suppress FRA-1 promoter activity
To assess the contribution of putative SRE and the ATF sites to the regulation of FRA-1 transcription in response to mitogenic signals, we generated additional promoter mutants lacking the TCF, CArG and ATF sites in the context of À379 to þ 32 fragment (Figure 3a) , and their impact on TPA and EGF induced expression was analysed. In response to TPA and EGF, a robust induction in the promoter activity was noticed with the wild-type promoter. However, mutation of the individual TCF site (AGGAA to AgTAc), the CArG box (CCATGTATGG to CCATGTTca), or the ATF site (GCTACGTCA to GgTAtGTtA) significantly diminished (>50%) both TPA and EGF-induced expressions of the reporter. These findings suggest that SRE and the ATF sites play an important role in regulating mitogen inducible FRA-1 transcription. Mutations within the TCF, CArG and ATF sites in the context of a heterologous (SV-40) minimal promoter also similarly reduced both TPA-and EGF-inducible FRA-1 transcription (data not shown). Collectively, these results suggest that SRE and the ATF site contribute to the induction of FRA-1 by mitogens.
Analysis of transcription factor binding to the À276/À239 bp FRA-1 promoter Based on the above studies, we chose a 38-bp DNA segment (À276/À239 region) containing the SRE (the TCF site and the CArG box), and the ATF site (see Figure 4a for sequence) for use in electrophoretic mobility shift assay (EMSAs) to identify protein factors that bind to it following TPA stimulation. The TCFCArG-ATF oligo formed three protein complexes, designated I, II and III. The intensity of these complexes was enhanced following TPA ( Figure 4b , compare lanes 1 and 2). The specificity of these complexes was analysed by competition assays using the unlabeled TCF-CArG-ATF (self) and other oligos: consensus TRE, consensus GC-box and the ATF oligo (see Figure 4a for sequence). Only the functional cis-acting elements, EBS, GC box (or Sp1 site) and TRE, located between -379 to À283 bp, are shown (see Adiseshaiah et al., 2003) . After 18-24 h, cells were serum-starved for 24 h and treated with vehicle (DMSO) or TPA (100 ng/ml) for 5 h. The firefly luciferase activity was normalized to that of Renilla luciferase, and the fold-activation by TPA was calculated using the values of unstimulated cells as 1.0 (n ¼ 3). (b) A549 cells were cotransfected with the indicated FRA-1 enhancer-reporter constructs or the pGL3 promoter vector (SV-Luc), and the luciferase expression following TPA (100 ng/ml) and EGF (50 ng/ml) stimulation was analysed. The À379/À237 SV-Luc construct bearing a mutation within -318 TRE was also used. Luciferase activity was analysed as described above for panel A, and the values of unstimulated cells transfected with SV-Luc as 1.0 (n ¼ 3). All experiments were performed at least twice GAGCAGAAACGGAGGTTAGCCCAGGCCTCGAGAGG-GCTGGGGCGGGGCGCGGGCTCTGGCAGGTGCGTCAG ----GGGAACCTTGGCTAGTCTTAACGGGGCGGGGCGCAGTTGCAAGCCCCAACTTCGGCAAGGTGCGTCAG ----GGGAACCTTGACTAGTCTGGACGGGGCGGGGCGCACGTACAAGCCCCAACCTCTGCTAGGTGCGTCAA * *** * *** * * * * ** ** * * * * ** * ********** TCCGCAGGGAACCCGGGGCTCCACCTGGGCGCGGCGAGGAAGTTACACCATGTATGGGCAGCTACGTCAGGGGG -----GGGGAATCCTCGG-TGCACCTGGGCGCGGCAAGGAAATTGCACCATGTATGGGCAGCTGCGTCAGAGGG -----GGGGAATCCTCGC-TGCACCTGGGCGCGGCAAGGAAATTGCACCATGTATGGGCAGCTGCGTCAGAGGG ***** ** * * ************** ***** ** ****************** ****** *** rfra-1 EMSAs were performed with the 32 P-end-labeled TCF-CArG-ATF probe using 2 mg of nuclear extracts isolated from A549 cells treated without (À) or with TPA ( þ ) for 90 min. For competition experiments, nuclear extracts were incubated for 10 min with 50-or 100-fold excess unlabeled oligo TCF-CArG-ATF (self) and 50-fold in case for c-FOS SRE, FRA-1-SRE, TRE or GC box. A 10-, 50-or 100-fold excess oligos was used in case of ATF-site (lanes 9-12). A representative EMSA autoradiogram from two independent experiments is shown. (c) Supershift analysis of the complexes formed at TCF-CArG-ATF. Nuclear extracts isolated from A549 (lanes 1-8) and MCF-7 (lanes 9-18) cells treated without (À) or with TPA ( þ ) were incubated without (Con) or with the indicated antibodies or IgG for 2 h on ice prior to the addition of labeled probe. (d) Supershift analysis with anti-ATF1 and anti-CREB antibodies. The indicated antibodies were incubated with the labeled probe in the absence of nuclear extracts (lanes 17-19) to determine the specificity of the supershifted complexes. Note that to better visualize both supershifted (SS) and/or blocked DNA-protein complexes gels were exposed for a longer and shorter time points. Open arrow indicates the position of supershifted SRF complex (SRF-SS) Although consensus TRE (lane 7) significantly diminished the formation of complex II, it had no such effect on complex I formation. In contrast, the consensus GC box had no appreciable effect on any of the three complexes (lane 8). To determine the specificity of ATF protein binding to the FRA-1 promoter, competition assays were performed using the unlabeled ATF site of the FRA-1 promoter (Figure 4b, lanes 9-12) . The FRA-1 ATF oligo strongly reduced the formation of complex II in a concentration-dependent manner. Collectively, these observations suggest that the TCF, SRF and ATF-like proteins bind to the À276/À239 region.
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We next used antibodies specific to various transcription factors to characterize the nature of the protein complexes binding to the TCF-CArG-ATF sites of the FRA-1 promoter (Figure 4c ). In unstimulated (À) and TPA-stimulated ( þ ) A549 and MCF cells, the anti-SRF antibody 'supershifted' complex I (Figure 4c , lanes 2 and 6). Note that in TPA-stimulated cells, the binding of SRF (lane 6) was slightly higher than in the control (lane 2). The anti-Elk1 antibody specifically decreased the formation of complex II in untreated (lane 3) and TPAstimulated (lane 7) cells, while anti-SAP1 antibody caused no appreciable effect (lanes 4 and 8). To better visualize supershifted and blocked DNA-protein complexes formed with nuclear extracts of A549 cells, EMSA gels were exposed for a longer and a shorter time, respectively (Figure 4c To further confirm the binding of above transcription factors, we have used oligos containing the TCF-CArG or SRE (Figure 5a ) and the ATF (Figure 5b ) sites of the FRA-1 promoter as probes in EMSAs. As seen with a full-length probe, incubation of nuclear extracts with the TCF-CArG probe yielded three specific complexes, I, II and III. The addition of anti-SRF completely shifted the complex I, while it significantly blocked the TCF complex II in A549 (lanes 3 and 4) and MCF-7 (lanes 12 and 13) cells. When incubated with the probe alone SRF antibody yielded no such supershift (Figure 5a , lane1). Anti-Elk1 antibody specifically decreased the complex II formation both in A549 (lanes 6 and 7) and MCF-7 (lane 14 and 15) cells. Anti-SAP1 antibody (lanes 16 and 17) also had a similar effect both in A549 (data not shown) and MCF-7 (Figure 5a , lanes 16 and 17) cells. Upon incubation of nuclear extracts with the ATF site formation of a single specific complex was noted (Figure 5b ). The anti-ATF1 antibodies (lanes 2 and 5) markedly blocked the formation of this complex, while the CREB antibodies (lanes 3 and 6) supershifted the complex in nuclear extracts isolated from control and TPA-treated A549 cells. ATF1 and CREB antibodies used in the present study do not crossreactive with other ATF/CREB transcription factors. Taken together, these results (Figures 4 and 5) indicate that The FRA-1 promoter is occupied by SRF, Elk1, CREB and ATF proteins in vivo
Although the EMSA results suggest the engagement of Elk1, SRF, ATF1 and CREB with the enhancer elements derived from the FRA-1 promoter, they do not directly address whether the endogenous FRA-1 promoter recruits these factors or not. We have shown earlier the recruitment of c-Jun to the endogenous FRA-1 promoter in response to TPA treatment (Adiseshaiah et al., 2003) . To determine whether SRF, Elk1, CREB and ATF1 are similarly recruited to the promoter in vivo, we performed a ChIP assay using the crosslinked chromatin fragments prepared from control and TPA-stimulated A549 cells ( Figure 6 ). In separate reactions, chromatin was immunoprecipitated using the anti-SRF, anti-Elk1, anti-CREB or anti-ATF1 antibodies. Nonimmune IgG was used as a negative control for these studies ( Figure 6 ). We also used a positive control IP reaction with anti-c-Jun-antibody in parallel to demonstrate the recruitment of c-Jun. DNAs eluted from the immunoprecipitated chromatin fragments were PCR amplified using FRA-1 promoter-specific primers. As expected, ChIP assays using the nonimmune IgG showed no amplification of the FRA-1 promoter. The SRF, Elk1, CREB and ATF1 proteins were present in the basal transcriptional complex formed with the FRA-1 promoter in the unstimulated state (lanes 1-3) . TPA treatment did not significantly enhance the recruitment of these proteins to the promoter (lanes 4-6). This finding is consistent with previous reports that have shown a constitutive occupation of SRF and Elk1 at the c-fos SRE (Herrera et al., 1989; Konig, 1991; Runkel et al., 1991; Tornaletti and Pfeifer, 1995) . In contrast, there was a significant increase in c-Jun recruitment to IgG was used as a negative control. PCR reaction with control DNA (1 ng of 379-Luc plasmid) and no template was used as a positive and negative control, respectively. The ChIP assays were performed with three independent samples at least twice to obtain reproducible results. IP ¼ immunoprecipitation FRA-1 regulation by SRF and Elk1 P Adiseshaiah et al the FRA-1 promoter after TPA stimulation (lanes 4-6), as compared with unstimulated cells (lanes 1-3) .
SRF, Elk1, ATF1 and CREB regulate TPA-inducible
FRA-1 transcription
To support the physical interaction studies (ChIP and EMSA), we next determined the transcription activating effects of SRF, Elk1, ATF1 and CREB. Previous studies (Brusselbach et al., 1995; Schreiber et al., 1997) , including ours (Adiseshaiah et al., 2003) , have reported a critical role for c-Jun in mediating the induction of FRA-1 by mitogenic stimuli. However, the effects of SRF and TCFs, and ATF1 and CREB in mediating FRA-1 transcription by extracellular stimuli have not yet been determined. Therefore, we have examined their roles in mediating FRA-1 induction by TPA. We have used expression vectors coding for dominant-negative mutants of SRF, Elk1, ATF1, ATF4 and CREB proteins. Coexpression of an SRF mutant (Lee et al., 1992) significantly suppressed TPA-induced FRA-1 promoter activity (Figure 7a) . Similarly, an Elk1 mutant (Yang et al., 1998) and an ATF1 mutant (Gupta and Prywes, 2002) markedly diminished TPA-inducible expression of the reporters (Figure 7b) . A mutant form of CREB protein also inhibited TPA-inducible expression of the reporter (Figure 7c ). In contrast, coexpression of ATF4-mt did not suppress TPA induced FRA-1 promoter activity (Figure 7d ). Collectively, these results suggest that SRF and TCF proteins, such as Elk1, ATF1 and CREB proteins regulate TPA-inducible FRA-1 expression.
Silencing of SRF, Elk1 and c-JUN expression significantly suppresses TPA-stimulated FRA-1 promoter activity
To examine whether attenuation of SRF, Elk1 and c-JUN expression alters FRA-1 promoter activity, A549 cells were transfected with the 379-Luc promoter reporter construct along with 20 nM of siRNAs specific for each of these transcription factors. After 36 h, cells were serum-starved for 12 h prior to TPA stimulation and luciferase activity was measured. We have chosen 20 nM siRNA in our experiments (Figure 8a ) although it suppressed B50% of the total levels of SRF, Elk1 and c-JUN proteins (data not shown). We could not escalate the dose of these siRNAs in these experiments because at higher concentrations (50-100 nM) these siRNAs exhibited nonspecific inhibitory effects (data not shown). Both SRF (Figure 8a , top panel, lanes 5 and 6) and Elk1 ( Figure 8a , bottom panel, lanes 5 and 6) siRNAs specifically reduced the SRF and Elk1 protein levels as compared to transfection reagent control (RC, lanes 1 and 2) and the negative control siRNA (NCsi, lanes 3 and 4). The siRNAs exerted no discernible inhibitory effect on the expression of ERK2 protein (internal control). As shown in Figure 8b , incubation of A549 cells in the presence of Elk1, SRF or c-JUN siRNAs caused a significant (P-values o0.002, o0.001, and o0.002, respectively) decrease in the TPA-stimulated FRA-1 promoter activity as compared to the NCsi (Figure 8b , bar 2). However, no appreciable difference was detectable between transfection reagent (bar 1) and NCsi (bar 2) transfected cells. These results suggest a role for SRF, Elk1 and c-JUN in TPA-induced FRA-1 transcription.
Overexpression of SRF mutant suppresses c-JUN stimulated FRA-1 promoter activity
We have recently reported that c-Jun-enhanced the induction of FRA-1 is mediated in part through TRE located at À318 (Adiseshaiah et al., 2003) . We therefore investigated whether SRE is required for this c-Junenhanced FRA-1 transcription. To examine this aspect, we transfected cells with an srf mutant along with the 379-Luc and pRK-TL plasmids in the presence of an empty or a c-jun expression vector. As expected, c-Jun markedly stimulated reporter upon coexpression. However, mutant SRF protein significantly suppressed cJun-enhanced FRA-1 promoter activity (Figure 9a ). In contrast, coexpression of a mutant form of ATF4 transcription factor along with c-Jun did not inhibit the FRA-1 promoter activity. The disruption of the individual TCF, CArG box, and ATF sites, located at position À274, À263, and À248, respectively, also strongly inhibited the c-Jun-enhanced reporter expression (data not shown). Together, these observations and the data presented in Figure 3 suggest a requirement for the SRE and ATF sites for a maximal stimulation of the FRA-1 promoter by c-Jun and mitogens, such as TPA.
The À379 to þ 32 bp 5 0 -flanking region of FRA-1 is sufficient for a temporal regulation of the reporter like the endogenous gene
To define whether À379 to þ 32 bp region of FRA-1 promoter construct recapitulates the regulatory profile of the endogenous gene, cells were transfected with the 379-Luc and pRK-TL plasmid constructs, serumstarved for 24 h, and then stimulated with TPA. Lysates were prepared after 0, 15, 30, 60 or 90 min of stimulation and luciferase activity was determined (Figure 10a) . No significant change in the promoter activity occurred up to 30-min post-TPA stimulation. In contrast, FRA-1 promoter activity is nearly four-fold higher by 60 min and remained high until 180 min. To analyse the endogenous FRA-1 and c-FOS expression, cell cultures grown in parallel were treated with TPA for 0-90 min, total RNA was isolated, and the endogenous mRNA levels were analysed by real-time PCR (Figure 10b ). As anticipated, TPA maximally stimulated the c-FOS mRNA expression by 30 min, as compared to the '0' min control (right panel). In contrast, no significant change in the levels of FRA-1 mRNA was noticed at this time point (left panel). However, FRA-1 mRNA was maximally expressed at 90 min after TPA stimulation (bar 5, left panel), whereas c-FOS expression returned to basal level at this time point (bar 5, right panel). Together, these results show that the -379 to þ 32 bp fragment of FRA-1 promoter contains sufficient necessary elements that temporally mimic the induction profile of the endogenous gene.
Discussion
The present study demonstrates for the first time that the À276/À237 bp region of FRA-1, containing the TCF, CArG and ATF sites is necessary for the mitogen inducible expression of FRA-1. This DNA segment is highly conserved across species and is homologous to that of c-FOS SRE. Importantly, we have demonstrated a requirement for both the SRE and the upstream À318 TRE for inducible FRA-1 transcription. Thus, the induction of FRA-1 by mitogenic stimuli appears to be regulated by a strong interdependence and cooperative interactions between multiple factors binding at the À379/À237 enhancer. These multiprotein combinatorial interactions probably provide for both cell-type-and stimulus-specific activation of FRA-1 in various cell types. Such interactions may allow for the integration of various signaling networks at the FRA-1 promoter in response to diverse mitogenic stimuli.
The involvement of the SRE, which is present in the regulatory regions of many immediate early genes such as fos-B, Egr1, Egr2, and junB, in various cellular responses to a wide variety of extracellular stimuli has been clearly established (Treisman, 1995) . Considerable progress has been made in our understanding of the components that mediate SRE-dependent c-fos regulation in response to different signaling pathways activated by diverse stimuli (Whitmarsh et al., 1995; Price et al., 1996) . Genomic footprinting and DNA binding assays have revealed that the SRE of c-fos is constitutively occupied both in vivo and in vitro by protein factors, SRF and Elk1 (Herrera et al., 1989; Konig, 1991; Runkel et al., 1991; Tornaletti and Pfeifer, 1995) , which play a critical role in mediating c-fos transcription in response to diverse stimuli. In contrast to our findings, Tsuchiya et al. (1993) failed to detect SRF binding to the CArG box of FRA-1 promoter in vitro. Although this discrepancy could be attributed to different experimental conditions, ChIP assays revealed that SRF and Elk1 proteins bound to the endogenous FRA-1 promoter in the unstimulated state. Overexpression of SRF and Elk1 mutant proteins or the RNAimediated attenuation of SRF and Elk1 expression significantly suppressed TPA-induced response of the promoter (Figures 7 and 8) . Our results are consistent with the recent identification of fra-1 as a target of SRF in a study that profiled gene expression in the NIH3T3 cells (Selvaraj and Prywes, 2004) . Collectively, these results support an important role for SRF in regulating FRA-1 transcription.
The TCFs (e.g. Elk1 and SAP1, SAP2/Net-b), which are variably expressed in different cell types, act as downstream effectors in various signaling networks initiated by a several different extracellular stimuli. The induction of c-fos and fos-B by diverse stimuli in different cell types is regulated by the activation and assembly of SRF and TCFs, such as Elk1 and SAP1, at the SRE (Whitmarsh et al., 1995; Treisman, 1996) . Consistent with this, our experiments clearly show that, in addition to SRF, Elk1 also regulates FRA-1 induction by TPA. ChIP assays revealed the binding of Elk1 to the endogenous FRA-1 promoter (Figure 6 ). Furthermore, Elk1 phosphorylation is tightly correlated with the activation of ERK1 and ERK2 MAP kinases following TPA and EGF treatment, and the inhibition of ERK Collectively, these results support a critical role for Elk1 in mediating SRE-dependent FRA-1 induction. These results are also in agreement with previous reports that showed an attenuation of mitogen-inducible FRA-1 mRNA expression by inhibitors of ERK signaling (Cook et al., 1999; Hurd et al., 2002; Ramos-Nino et al., 2002; Vial and Marshall, 2003) . Based on data obtained from our current and previous studies (Adiseshaiah et al., 2003) and those of others (Bergers et al., 1995; Brusselbach et al., 1995; Schreiber et al., 1997) , we propose the following model for the transcriptional induction of FRA-1 by mitogens, such as TPA (Figure 11 ). In the unstimulated state, the SRF, Elk1, ATF1 and CREB proteins are bound to the SRE. Upon TPA treatment, the activation of the MAP kinase cascades leads to an enhanced expression and phosphorylation of c-Jun, which then binds to DNA tightly. Simultaneously, TPA-activated MAP kinases may also phosphorylate Elk1 and ATF1/CREB proteins to enhance their transactivating functions. Subsequent to the binding of Jun:Fra-2 dimer (Adiseshaiah et al., 2003) to the À318 TRE, a c-Jun dependent cooperative interaction between factors binding at the À379/ À237 bp enhancer and the proximal promoter, drive transcription. SRE is known to be occupied by several factors that can either negatively or positively regulate transcription. For example, a recent study has shown that loss of ETS transcription factor, Net, results in constitutive activation of c-fos transcription (van Riggelen et al., 2005) . It is likely that the binding of cJun at À318 TRE destabilizes the binding of such negative factor(s) to the SRE, thereby setting stage to the initiation of mitogen-stimulated transcription. Further investigation is required to address this possibility.
Materials and methods
Cell culture
A549, a human alveolar type II-like tumorogenic epithelial cell line, was maintained in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) and antibiotics (Invitrogen, Carlsbad, CA, USA). The 1HAEo, a human bronchial epithelial cell line, was maintained in MEM containing 10% fetal calf serum. MCF-7, a breast cancer cell line, was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS.
Plasmids
The 379-Luc construct was generated by cloning the À379 to þ 32 bp 5'-flanking region of FRA-1upstream of the reporter firefly luciferase (Luc) gene (Adiseshaiah et al., 2003) , between the SacI and NheI sites of the pGL3 basic vector (Promega Corp., Madison). Mutants lacking various elements within the 379-Luc were generated by PCR. An enhancer fragment (-379 to -237) of the FRA-1 gene was PCR-amplified and ligated between the SacI and NheI sites of the pGL3 promoter vector, where the SV-40 early promoter drives the Luc gene expression. The pCMV-c-jun expression vector was provided by Michael Birrer (National Cancer Institute, Bethesda, MD, USA). The pCMV-based elk1 expression vector lacking amino acids 312 to 321 (Elk-DD) were kindly provided by Andrew Sharrocks (University of Manchester, UK). An SRF mutant, SRF-mt, lacking the transactivation domain (TAD) and an ATF1 mutant, ATF1-mt, with a serine to alanine mutation at position 63 were kindly provided by Ron Prywes (Columbia University, NY, USA). A CREB mutant, CREB-mt, having mutations in serine 133 phosphorylation site was generously provided by Richard H Goodman (Oregon University, OR, USA), and ATF4-mt was kindly given by Jawed Alam (Ochsner Clinic Foundation, New Orleans).
Transient transfection and reporter gene assays
Transient transfections were carried out as described earlier (Adiseshaiah et al., 2003) . In brief, cells were transfected at 70-80% confluence with 100 ng of FRA-1 promoter-reporter construct, 1 ng of Renilla luciferase vector (pRL-TK; Promega), and 25-100 ng of empty or expression plasmid. All transfections were performed using the FuGENE 6 reagent (Roche). After an overnight incubation, cells were serumstarved for 24 h and then treated with vehicle (DMSO), EGF (50 ng/ml) or TPA (100 ng/ml). Cellular extracts were assayed for firefly and Renilla luciferase activities, a commercially available kit (Promega). Firefly luciferase activity was normalized to that of Renilla luciferase, the internal transfection control. All experiments were performed in triplicate (n ¼ 3) and repeated at least twice. Data are expressed as the mean7s.e. and the statistical significance was determined using Student's t-test.
Small interfering RNA (siRNA) and gene expression analysis SMARTpool siRNA duplexes for human SRF (cat # M-009800-00), Elk1 (cat # M-003885-00), c-JUN (cat # M-003268-01) were purchased from Dharmacon, Inc. (Lafayette, CO, USA). A scrambled siRNA (cat # D-001206-06-05) was used as a negative control. A549 cells at 30-40% confluence were transfected with siRNAs using the TransIT-TKO transfection reagent (Mirus, Madison, WI, USA). In addition, a Cy3 labeled luciferase GL2 duplex, used to determine optimal conditions for siRNA transfection, were purchased FRA-1 regulation by SRF and Elk1 P Adiseshaiah et al from Dharmacon. The cells were harvested 48-72 h after transfection for analyses. Immunoblot analysis was carried out as described previously (Papaiahgari et al., 2004) . Membranes were probed with anti-SRF (SC-335X), anti-Elk1 (sc-355X) and anti-ERK2 (SC-154) (all obtained from Santa Cruz Biotech Inc., CA, USA) antibodies and developed using ECL-Plus reagent (Amersham Pharmacia Biotech). For reporter assays, A549 cells were transfected with 100 ng of 379-Luc promoter-reporter construct along with human Elk1, SRF, c-JUN or scrambled nonspecific siRNAs for 36 h. The final concentrations of siRNA used in each transfection were 20 nM. Cells were serum-starved overnight prior to stimulation with TPA (100 ng/ml) for 5 h. Luciferase activity was measured as described above.
Electrophoretic mobility shift assays (EMSAs)
Serum-starved A549 cells were treated with DMSO, EGF or TPA for 90 min, and nuclear extracts were prepared as described previously (Adiseshaiah et al., 2003) . Briefly, the EMSAs were performed using 2-3 mg of nuclear extract in a 20 ml of binding buffer (10 mM Tris-HCl, pH 7.5, with 50 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl 2 , 4% glycerol, 0.25 mg/ml poly dI-dC, and 0.5 mg salmon sperm DNA) on ice for 10 min prior to the addition of the appropriate 32 P-labeled double-stranded oligo probe. After incubating for 30 min at room temperature, samples were resolved on a 4% polyacrylamide gel containing 2% glycerol. To demonstrate the specificity of DNA : protein complex formation, nuclear extracts were incubated for 10 min with a 10-to 100-fold molar excess of the indicated unlabeled doublestranded oligos prior to the addition of labeled probe. For demonstrating the presence of a specific protein in the complexes, nuclear extracts were mixed with 1-2 mg of c-Jun (sc-45X), Jun-B (sc-46X), Jun-D (sc-74X), c-fos (sc-7202X), Fra-1 (sc-605X), Fra-2 (sc-604X), Elk1 (sc-355X), SAP1 (sc-13030X), SRF (sc-335X), ATF1 (sc-243X) (all obtained from Santa Cruz Biotechnology, CA, USA) and antiphospho-CREB (Cat # 06-519, Upstate Cell Signaling) antibodies and incubated on ice for 2 h prior to adding the probe.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out as described in our earlier publication (Adiseshaiah et al., 2003) . Briefly, cells (B1 Â 10 7 ) were stimulated with TPA (100 ng/ml) for 90 min, and ChIP was performed using a commercially available kit (Upstate Biotechnology Inc., Lake Placid, NY, USA). Chromatin was crosslinked by adding formaldehyde (1%) to the tissue culture medium for 10 min at 371C. A fraction of the soluble chromatin (1%) was saved for measurement of total chromatin input. Precleared chromatin was incubated with specific antibody for 18 h at 41C. Eluted DNA from the immunoprecipitated products was extracted after proteinase K digestion and used for PCR (40 cycles) with FRA-1 promoter-specific primers: À379 F (5 0 -GCGGAGCTCGCAGAAACGGAGG-3 0 ) and À237 R (5 0 -GGCGCTAGCCCCCTGACGTAGCTGCCCAT-3 0 ), which yield a 143-bp DNA product.
Real-time-PCR
Total RNA (2 mg) was reverse transcribed to cDNA using SuperScript First-Strand Synthesis cDNA kit according to the manufacturer's instruction (Invitrogen). TaqMan s Gene Expression Assays for FRA-1 (cat # Hs00759776_s1), c-FOS (Hs00170630_m1) and GAPDH (Hs99999905-m1) were purchased from Applied Biosystems (Foster City, CA, USA) and mRNA levels were quantified in triplicate using Applied Biosystems 7300/7500 Real-Time PCR system according to the supplier's recommendations. The absolute values for FRA-1 and c-FOS were normalized to that of GAPDH and the relative value from vehicle-treated control group was used as one arbitrary unit (AU).
Abbreviations AP-1, activator protein-1; ATF, activating transcription factor; ChIP, chromatin immunoprecipitation; EBS, Etsbinding site; EMSA, electrophoretic mobility shift assay; FRA-1 or FOSL-1, fos-related antigen 1; Luc, luciferase; TCF, ternary complex factor; TPA, 12-O-tetradecanoylphorbol-13-acetate; TRE, TPA response element; SRF, serum response factor; SRE, serum response element.
